Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.5B

Nov3Wed

Pre-Earnings Brief

UpcomingQ4-2024After Close5:00 PM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its expenses relative to its revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine and genetic research continue to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3 2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted with a slight decline of 0.19% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for its lead product candidates.
Commitment to managing operational costs effectively.
Plans to enhance investor communication regarding pipeline developments.

Expectations

Wall Street Expectations

Overall, expectations for Cogent's upcoming earnings are mixed, given its history of missing EPS estimates. Investors will be watching closely for any signs of improvement in revenue or R&D progress.

Bull Case

If Cogent can show improved EPS and robust revenue growth, it could signal effective management and strong future prospects, potentially driving the stock higher.

Bear Case

Conversely, continued losses and lack of revenue growth may raise concerns about the company's viability and lead to further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of clinical trials for key product candidates?

Updates on clinical trials will be crucial for understanding the potential for future revenue and market impact.

How is the company managing its R&D budget in light of recent losses?

Investors will want to know if the company can sustain its R&D efforts while controlling costs, which is vital for long-term success.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Cogent's pipeline to deliver significant breakthroughs, which could lead to better-than-expected results.

Supporting Evidence

Historical data shows that even with EPS misses, the stock has often reacted positively, indicating underlying investor confidence.

The options market is pricing a larger move than historical averages, suggesting that investors expect a surprise.

Management's commitment to R&D spending could yield unexpected positive results in upcoming trials.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Cogent can turn its clinical advancements into financial performance amidst ongoing losses.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would indicate improved operational efficiency.

Bear Confirmed If

Continued EPS losses greater than -$0.64 would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±10.44%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests the stock could rise by an average of 2.45%, confirming a positive outlook.

In-Line / Cautious

A cautious but in-line report may lead to minimal movement as investors await clearer guidance.

Miss

If the company misses expectations again, history suggests an average decline of 3.44%, raising further concerns about its financial stability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Any changes in R&D spending plans.
3Insights into market demand for their therapies.
4Management's outlook on future revenue streams.
5Responses to questions about operational efficiency.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Nov1

AEISReported

Advanced Energy Industries, Inc.

RecapView

Nov1

CNAReported

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its expenses relative to its revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3 2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted with a slight decline of 0.19% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for its lead product candidates.
Commitment to managing operational costs effectively.
Plans to enhance investor communication regarding pipeline developments.

Expectations

Wall Street Expectations

Overall, expectations for Cogent's upcoming earnings are mixed, given its history of missing EPS estimates. Investors will be watching closely for any signs of improvement in revenue or R&D progress.

Bull Case

If Cogent can show improved EPS and robust revenue growth, it could signal effective management and strong future prospects, potentially driving the stock higher.

Bear Case

Conversely, continued losses and lack of revenue growth may raise concerns about the company's viability and lead to further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of clinical trials for key product candidates?

Updates on clinical trials will be crucial for understanding the potential for future revenue and market impact.

How is the company managing its R&D budget in light of recent losses?

Investors will want to know if the company can sustain its R&D efforts while controlling costs, which is vital for long-term success.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Cogent's pipeline to deliver significant breakthroughs, which could lead to better-than-expected results.

Supporting Evidence

Historical data shows that even with EPS misses, the stock has often reacted positively, indicating underlying investor confidence.

The options market is pricing a larger move than historical averages, suggesting that investors expect a surprise.

Management's commitment to R&D spending could yield unexpected positive results in upcoming trials.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Cogent can turn its clinical advancements into financial performance amidst ongoing losses.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would indicate improved operational efficiency.

Bear Confirmed If

Continued EPS losses greater than -$0.64 would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±10.44%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests the stock could rise by an average of 2.45%, confirming a positive outlook.

In-Line / Cautious

A cautious but in-line report may lead to minimal movement as investors await clearer guidance.

Miss

If the company misses expectations again, history suggests an average decline of 3.44%, raising further concerns about its financial stability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Any changes in R&D spending plans.
3Insights into market demand for their therapies.
4Management's outlook on future revenue streams.
5Responses to questions about operational efficiency.